Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The androgenic vaginal ring program developed by Laboratorios Andromaco S.A. consists of investigational sustained-release delivery systems containing dehydroepiandrosterone (DHEA), testosterone, or a fixed-dose combination of both. These rings are designed for continuous vaginal administration to women with diminished ovarian reserve (DOR). The primary therapeutic goal is to increase local androgen concentrations in the ovarian environment, which is hypothesized to enhance follicular recruitment, increase the antral follicle count (AFC), and improve anti-Müllerian hormone (AMH) levels. By optimizing the androgenic microenvironment, the treatment aims to improve the ovarian response to stimulation in women undergoing fertility treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on androgenic vaginal ring.